Supporting an Early Diagnosis: Identifying Underlying Pathologies with Biomarkers
Henrik Zetterberg, MD, PhD, describes the core CSF biomarkers used in the diagnosis of Alzheimer’s disease (including tau and Aβ), and how the use of CSF biomarker ratios are superior to single biomarkers, for differential diagnosis across dementia etiologies. He also discusses emerging fluid biomarkers, such as neurofilament light chain and plasma biomarkers. He examines the use and results of fluid biomarker testing in the patient case study. James Leverenz, MD, then describes the role of imaging biomarkers, specifically magnetic resonance imaging (MRI), in the diagnosis of the patient in the case study.
Key Learning Objectives for Biogen’s ADPD 2019 Symposium:
- Understand the importance of an accurate and timely diagnosis of Alzheimer’s disease
- Review the diagnostic challenges of a mixed pathology in patients with Alzheimer’s disease
- Increase understanding of how comprehensive clinical assessments and a range of imaging and fluid biomarkers can be used in the timely diagnosis of a complex case of Alzheimer’s disease
- Raise awareness of the current healthcare system readiness for a paradigm shift to early diagnosis of Alzheimer’s disease
Disclosure: All panelists received honoraria from Biogen for participation in this symposium.
Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.